Sponsor
Hebei Medical University Fourth Hospital
Clinical research sponsor
How to interpret these research links
Connected source recordsThe exact organization name Hebei Medical University Fourth Hospital appears in 55 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
55 shownDalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast CancerNCT07492394 · lead sponsor · 2025-09-12
RECRUITINGEfficacy and Safety of Dalpiciclib in Hormone Receptor-positive Advanced Breast CancerNCT05578053 · lead sponsor · 2024-09-13
RECRUITINGPyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast CancerNCT07635342 · lead sponsor · 2024-04-30
RECRUITINGThe Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).NCT06217185 · lead sponsor · 2024-01-02
RECRUITINGDalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）NCT06107673 · lead sponsor · 2023-09-30
RECRUITINGDurvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)NCT06371482 · lead sponsor · 2023-06-01
RECRUITINGEfficacy and Safety of Tislelizumab for Lung Adenocarcinoma With Asymptomatic Brain MetastaticNCT06056115 · lead sponsor · 2023-05-01
RECRUITINGAdjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung CancerNCT05241028 · lead sponsor · 2022-05-01
RECRUITINGChemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast CancerNCT05525767 · lead sponsor · 2022-03-31
RECRUITINGClinical Study of Breast Conserving Surgery Combined With Intraoperative Radiotherapy for Early Breast CancerNCT06375798 · lead sponsor · 2020-11-19
RECRUITINGNab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast CancerNCT04138719 · lead sponsor · 2019-11-20
RECRUITINGNab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast CancerNCT04159142 · lead sponsor · 2019-11-20
RECRUITINGQL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant ChemotherapyNCT07782840 · lead sponsor · 2026-10-01
NOT_YET_RECRUITINGTrastuzumab/Pertuzumab With Fulvestrant and Kurmoxilil in HR+/HER2+ Early Breast CancerNCT07857226 · lead sponsor · 2026-09-01
NOT_YET_RECRUITINGOlaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast CancerNCT05522491 · lead sponsor · 2026-09-01
NOT_YET_RECRUITINGA Real-World Study on the Impact of Different Adjuvant Treatment Regimens on Prognosis in Non-pCR Patients With HER2-Positive Breast Cancer After Neoadjuvant TherapyNCT07540520 · lead sponsor · 2026-08-02
NOT_YET_RECRUITINGNeoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.NCT07528898 · lead sponsor · 2026-05-01
NOT_YET_RECRUITINGctDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With RadiotherapyNCT07410611 · lead sponsor · 2026-02-10
NOT_YET_RECRUITINGThis Study Aims to Optimize Neoadjuvant Therapy for HER2-positive Breast Cancer by Implementing a Dynamic Monitoring-guided Treatment Strategy.NCT06973525 · lead sponsor · 2025-09-01
NOT_YET_RECRUITINGEfficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical StudyNCT07004335 · lead sponsor · 2025-07-01
NOT_YET_RECRUITINGNeratinib in Extended Adjuvant Treatment for HER2+ Early Breast Cancer With pCR But High-Risk Features: A Hebei Multi-Center Real-World StudyNCT07019272 · lead sponsor · 2025-06-30
NOT_YET_RECRUITINGTislelizumab in Combination with Chemotherapy ± Radiotherapy for Extensive-Stage Oligometastatic Small Cell Lung Cancer.NCT06851819 · lead sponsor · 2025-03-01
NOT_YET_RECRUITINGA Real-world Study of Adebrelimab Combined With Chemotherapy±Chest Radiotherapy in Patients With Extensive Stage Small Cell Lung CancerNCT06323265 · lead sponsor · 2024-03-26
UNKNOWNDalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage Ⅱ-Ⅲ HR-positive/HER2-negative Breast CancerNCT05512780 · lead sponsor · 2022-09-10
UNKNOWNTargeted Next Generation Sequencing for the Efficacy of Trastuzumab Neoadjuvant Chemotherapy in Breast CancerNCT03728829 · lead sponsor · 2021-07-01
UNKNOWNNeoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast CancerNCT04290793 · lead sponsor · 2020-03-01
ACTIVE_NOT_RECRUITINGA Trail of Neoadjuvant Endostar in Combination With Chemotherapy in Breast CancerNCT01907529 · lead sponsor · 2019-08-01
UNKNOWNNab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for TNBCNCT04067102 · lead sponsor · 2019-05-10
WITHDRAWNPyrotinib in Combination With Nab-paclitaxel in Patients With HER2-positive Advanced Breast Cancer: an Exploratory StudyNCT03919253 · lead sponsor · 2019-04-30
UNKNOWNApatinib in Neoadjuvant Therapy for Patients With Breast CancerNCT03580395 · lead sponsor · 2017-06-01
UNKNOWNProspective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast CancerNCT03086785 · lead sponsor · 2016-11-24
UNKNOWNDoxorubicin Hydrochloride Liposome Injection Combination With Cyclophosphamide vs Pirarubicin Combination With Cyclophosphamide in Patients With Locally Advanced Breast CancerNCT02903524 · lead sponsor · 2016-09-01
UNKNOWNA Dose Increase Finding Study of Doxorubicin Hydrochloride Liposome Injection for Patients With Breast CancerNCT03017404 · lead sponsor · 2015-05-01
COMPLETEDNeoadjuvant Chemotherapy With a Combination of Pegylated Liposomal Doxorubicin (Caelyx®) and Paclitaxel in Breast CancerNCT03221881 · lead sponsor · 2015-01-01
COMPLETEDClinical Observation of S1 Capsule for Stage Ⅱ-ⅢA Non-small Cell Lung Cancer After Complete ResectionNCT02223611 · lead sponsor · 2014-12-01
UNKNOWNRomiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid TumorsNCT07586826 · collaborator · 2025-12-22
RECRUITINGSurgery vs. No Surgery for Primary Tumor in De Novo Stage IV Breast Cancer With Solitary Bone MetastasesNCT07687225 · collaborator · 2026-09-01
NOT_YET_RECRUITINGA Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer.NCT07307443 · collaborator · 2026-02-01
NOT_YET_RECRUITINGA Phase II Study of QL1706 and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Non-Small Cell Lung Cancer.NCT07200947 · collaborator · 2025-12-01
NOT_YET_RECRUITINGA Phase II Study of QL1706 With Anti-angiogenesis Therapy and Chemotherapy in Extensive-stage Small Cell Lung Cancer.NCT07083375 · collaborator · 2025-08-01
NOT_YET_RECRUITINGApatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast CancerNCT05759572 · collaborator · 2023-03-01
ACTIVE_NOT_RECRUITINGEnsartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 MutationNCT05491811 · collaborator · 2022-08-01
ACTIVE_NOT_RECRUITINGMulti-center Study of Deep Learning AI in Breast MassNCT05443672 · collaborator · 2021-08-12
UNKNOWNThe Characteristics, Treatment Patterns and Prognosis of Chinese Male Breast Cancer: A Real-world StudyNCT06220630 · collaborator · 2021-08-01
UNKNOWNA Clinical Trial of TAA06 Injection in Advanced Solid TumorsNCT05190185 · collaborator · 2021-06-01
UNKNOWNA Study Evaluating Drug-Drug Interaction (DDI) Between HSK16149 Capsules and Metformin Hydrochloride TabletsNCT04841720 · collaborator · 2021-04-01
UNKNOWNStudy of Efficacy, Safety, and Pharmacokinetics of FCN-437c in Combination With Fulvestrant or Letrozole+GoserelinNCT05004142 · collaborator · 2020-06-30
UNKNOWNPostmastecomy Internal Mammary Nodal Irradiation for High-risk Breast Cancer PatientsNCT04320979 · collaborator · 2020-05-08
ACTIVE_NOT_RECRUITINGCirculating Tumor DNA Longitudinal Monitoring in Stage III-IV Lung Cancer PatientsNCT03664843 · collaborator · 2018-11-09
UNKNOWNPulmonary Ventilation/Perfusion Imaging for the Prediction of Postoperative Residual Pulmonary FunctionNCT03357094 · collaborator · 2017-09-30
UNKNOWNSafety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast CancerNCT04103853 · collaborator · 2017-09-06
COMPLETEDA Hospital Based Survey on Lung Cancer Related-pain in Northern ChinaNCT03189277 · collaborator · 2017-06-01
UNKNOWNMulticenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer(CABC006)NCT02878057 · collaborator · 2016-05-01
COMPLETEDChemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung AdenocarcinomaNCT02621333 · collaborator · 2015-10-01
TERMINATEDErlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR MutationsNCT01410214 · collaborator · 2011-05-01
UNKNOWNDrugs studied in this sponsor's trials
18 mapped RxNorm conceptsThese drug records are connected through ClinicalTrials.gov studies listing Hebei Medical University Fourth Hospital as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.
cyclophosphamide3
bevacizumab2
ensartinib2
pertuzumab2
trastuzumab2
capecitabine1
cisplatin1
cyclophosphamide Injection1
cyclophosphamide RxCUI 3002 · Lead sponsor in 3 linked trial(s) · 1 currently recruiting
3 trials
bevacizumab RxCUI 253337 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting
2 trials
ensartinib RxCUI 2712546 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting
2 trials
pertuzumab RxCUI 1298944 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting
2 trials
trastuzumab RxCUI 224905 · Lead sponsor in 2 linked trial(s) · 1 currently recruiting
2 trials
capecitabine RxCUI 194000 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting
1 trial
cisplatin RxCUI 2555 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
cyclophosphamide Injection RxCUI 1734916 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting
1 trial
docetaxel RxCUI 72962 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
docetaxel Injection RxCUI 1860479 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting
1 trial
durvalumab RxCUI 1919503 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting
1 trial
epirubicin RxCUI 3995 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
erlotinib RxCUI 337525 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting
1 trial
fulvestrant RxCUI 282357 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
letrozole RxCUI 72965 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting
1 trial
olaparib RxCUI 1597582 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
paclitaxel RxCUI 56946 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
vinorelbine RxCUI 39541 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
Sponsor roles
lead sponsor35
collaborator20
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.